DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia

Information source: Holdsworth House Medical Practice
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV

Phase: N/A

Status: Completed

Sponsored by: Holdsworth House Medical Practice

Official(s) and/or principal investigator(s):
Mark Bloch, Dr., Principal Investigator, Affiliation: Holdsworth House Medical Practice

Summary

This observational study will aim to determine long-term atazanavir experience in a high HIV caseload primary care practice in Sydney, Australia.

Clinical Details

Official title: Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome: Proportion of HIV-1 infected participants with atazanavir experience

Secondary outcome:

Proportion of HIV-1 infected participants with atazanavir experience

Proportion of HIV-1 infected participants with atazanavir experience

Proportion of HIV-1 infected participants with atazanavir experience

Proportion of HIV-1 infected participants with atazanavir experience

Detailed description: This observational study will aim to determine long term atazanavir experience in HIV-1 infected patients in a primary care setting. 3. OBJECTIVES OF THE STUDY i. Primary objective Long-term (2 years or greater) atazanavir experience in HIV-1 infected patients in a primary care setting through retrospective data collection. ii. Secondary objectives 1. To illustrate long term therapeutic efficacy of atazanavir in ART naïve and experienced HIV-1 infected patients. 2. To illustrate long term tolerability to atazanavir in ART naïve and experienced HIV-1 infected patients. 3. To identify ART treatment history in ART naïve and experienced HIV-1 infected patients on ATV. 4. To identify contraindicated therapy in ART naïve and experienced HIV-1 infected patients on ATV.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. HIV-1 positive 2. Have commenced ATV between 2002-2008 (Baseline) 3. Follow-up data (clinical and laboratory) available from baseline Exclusion Criteria: 1. Patients not commenced ATV between 2002-2008 2. No follow-up data (clinical and laboratory) available from baseline 3. Patient 'lost to follow-up' with < 2 years of follow-up data (Clinical and laboratory)

Locations and Contacts

Holdsworth House Medical Practice, Sydney, New South Wales 2010, Australia
Additional Information

Starting date: April 2010
Last updated: September 8, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017